Relutrigine (PRAX-562) is an orally active inhibitor of persistent sodium channel . Relutrigine potently and preferentially inhibits persistent I Na induced by ATX-II (Nav 1.5 activator) or the SCN8A mutation N1768D with IC 50 values of 141 nM and 75 nM, respectively. Relutrigine exhibits potent use-dependent block and reduces neuronal intrinsic excitability. Relutrigine has effective anticonvulsant activity.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Sodium Channel
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.